MX2018016121A - Preparacion de anticuerpos monoclonales marcados con 212pb. - Google Patents

Preparacion de anticuerpos monoclonales marcados con 212pb.

Info

Publication number
MX2018016121A
MX2018016121A MX2018016121A MX2018016121A MX2018016121A MX 2018016121 A MX2018016121 A MX 2018016121A MX 2018016121 A MX2018016121 A MX 2018016121A MX 2018016121 A MX2018016121 A MX 2018016121A MX 2018016121 A MX2018016121 A MX 2018016121A
Authority
MX
Mexico
Prior art keywords
preparation
monoclonal antibodies
labeled monoclonal
lead
generation
Prior art date
Application number
MX2018016121A
Other languages
English (en)
Inventor
Hartvig Larsen Roy
Original Assignee
Sciencons AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciencons AS filed Critical Sciencons AS
Publication of MX2018016121A publication Critical patent/MX2018016121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a la generación de plomo-212 para uso terapéutico. Específicamente, son métodos relacionados con las modalidades de generación de proteínas radiomarcadas a base de plomo-212, tales como radioinmunoconjugados, de la presente invención.
MX2018016121A 2016-06-24 2017-06-23 Preparacion de anticuerpos monoclonales marcados con 212pb. MX2018016121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16176263 2016-06-24
PCT/EP2017/065508 WO2017220767A1 (en) 2016-06-24 2017-06-23 Preparation of 212pb labeled monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX2018016121A true MX2018016121A (es) 2019-05-30

Family

ID=56263569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016121A MX2018016121A (es) 2016-06-24 2017-06-23 Preparacion de anticuerpos monoclonales marcados con 212pb.

Country Status (9)

Country Link
US (1) US11306038B2 (es)
EP (1) EP3474904A1 (es)
JP (1) JP7176958B2 (es)
CN (1) CN109310789B (es)
AU (1) AU2017281649B2 (es)
CA (1) CA3026599A1 (es)
IL (1) IL263808A (es)
MX (1) MX2018016121A (es)
WO (1) WO2017220767A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
EP4385045A1 (en) 2021-08-11 2024-06-19 Nuclear Research and Consultancy Group System and method of the production and isolation of charged radionuclides
WO2023161840A1 (en) * 2022-02-24 2023-08-31 Alpha Tau Medical Ltd. Convection-enhanced diffusing alpha-emitter radiation therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
DE10040771A1 (de) 2000-08-21 2002-03-14 Altmann Therapie Gmbh & Co Kg Neue, 224Ra enthaltende, radiotherapeutisch wirksame Formulierungen und Verfahren zu ihrer Herstellung
DE10347459B3 (de) * 2003-10-13 2005-05-25 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
CN105535967B (zh) * 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
WO2012032043A1 (en) 2010-09-07 2012-03-15 Areva Med Llc 212 pb imaging
US9433690B1 (en) 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
SG11201706849SA (en) 2015-02-26 2017-09-28 Sciencons AS Radiopharmaceutical solutions with advantageous properties
NO3061464T3 (es) * 2015-02-26 2018-03-24

Also Published As

Publication number Publication date
WO2017220767A1 (en) 2017-12-28
AU2017281649B2 (en) 2023-07-27
US20190194087A1 (en) 2019-06-27
JP7176958B2 (ja) 2022-11-22
EP3474904A1 (en) 2019-05-01
IL263808A (en) 2019-02-03
CN109310789A (zh) 2019-02-05
US11306038B2 (en) 2022-04-19
CN109310789B (zh) 2021-12-03
CA3026599A1 (en) 2017-12-28
JP2019523232A (ja) 2019-08-22
AU2017281649A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
EA202190808A2 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12016501366A1 (en) Novel anti-baff antibodies
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2023006416A (es) Anticuerpos, usos y metodos.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor
PH12019502694A1 (en) Anti-trkb antibodies
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof